Progression of no-reflow prevention and treatment in percutaneous coronary intervention

Abstract

Abstract: As percutaneous coronary intervention is widely used in clinic, more and more acute ST-segment elevation myocardial infarction patients undergo direct PCI. However, no-reflow phenomenon seriously affects the prognosis of patients during emergent PCI. The possible mechanisms and therapies of no-reflow phenomenon will be introduced briefly in this review.

Key words: Percutaneous coronary intervention, No-reflow, Slow reflow, Vasodilator agents, Platelet glycoprotein receptor antagonist, Thrombus aspiration, Distal protection equipment

CLC Number:

R541.4

LI Xiao-qian, KE Yong-sheng. Progression of no-reflow prevention and treatment in percutaneous coronary intervention[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2011, 16(5): 595-600.

References

[1] Abbo KM, Dooris M, Glazier S, et al. Features and outcome of no-reflow after percutaneous coronary intervention [J]. Am J Cardiol, 1995, 75(12): 778-782.
[2] Piana RN, Paik GY, Moscucci M, et al. Incidence and treatment of 'no-reflow' after percutaneous coronary intervention[J]. Circulation, 1994, 89(6):2514-2518.
[3] Yip HK, Chen MC, Chang HW, et al. Angiographic morphologic features of infarct related arteries and timely reperfusion in acute myocardial infarction: predictors of slow-flow and no-reflow phenomenon [J]. Chest, 2002, 122(4): 1322-1332.
[4] Kenner M, Zajace J, Kondos GT, et al. Ability of the no-reflow phenomenon during an acute myocardial infarction to predict left ventricular dysfunction at one-month follow-up[J]. Am J Cardiol, 1995, 76(12): 861-868.
[5] Smart SC, Sawada S, Ryan T, et al. Low-dose dobutamine echocardiography detects reversible dysfunction after thrombolytic therapy of acute myocardial infarction[J]. Circulation, 1993, 88(2): 405-415.
[6] Sanchis J, Munoz J, Chorro FJ, et al. Stunned myocardium after thrombolytic treatment. Identification by dobutamine echocardiography and role of the residual stenosis in the infarction artery[J]. Int J Cardiol, 1996, 53(1): 5-13.
[7] Matetzky S, Freimark D, Chouraqui P, et al. The distinction between coronary and myocardial reperfusion after thrombolytic therapy by clinical markers of reperfusion [J]. J Am Coll Cardiol, 1998, 32(5): 1326-1330.
[8] Zeymer U, Schrode R, Tebbe U, et al. Non-invasive detection of early infarct vessel patency by resolution of ST-Segment elevation in patients with thrombolysis for acute myocardial infarction [J]. Eur Heart J, 2001, 22(9): 769-775.
[9] Vijayalakshmi K, Whittaker VJ, Kunadian B, et al. Prospective, randomized, controlled trial to study the effect of intracoronary injection of verapamil and adenosine on coronary blood flow during percutaneous coronary intervention in patients with acute coronary syndromes[J]. Heart, 2006, 92(9): 1278-1284.
[10] Parikh KH, Chag MC, Shah KJ, et al. Intracoronary boluses of adenosine and sodium nitroprusside in combination reverses slow/no-reflow during angioplasty: a clinical scenario of ischemic preconditioning [J]. Can J Physiol Pharmacol, 2007, 85(3/4): 476-482.
[11] Ross AM, Gibbons RJ, Stone GW, et al. A randomized, double blinded, placebo-controlled multicenter trial of adenosine as an adjunct to reperfusion in the treatment of acute myocardial infarction(AMISTAD-Ⅱ) [J]. J Am Coll Cardiol, 2005, 45(11): 1775-1780.
[12] Kawai Y, Hisamatsu K, Matsubara H, et al. Intravenous administration of nicorandil immediately before percutaneous coronary intervention can prevent slow coronary flow phenomenon [J]. Eur Heart J, 2009, 30(7): 765-772.
[13] Ota S, Nishikawa H, Takeuchi M, et al. Impact of nicorandil to prevent reperfusion injury in patients with acute myocardial infarction: Sigmart Multicenter Angioplasty Revascularization Trial (SMART) [J]. Circ J, 2006, 70(9): 1099-1104.
[14] Amit G, Cafri C, Yaroslavtsev S, et al. Intracoronary nitroprusside for the prevention of the no-reflow phenomenon after primary percutaneous coronary intervention in acute myocardial infarction. A randomized, double-blind, placebo-controlled clinical trial[J]. Am Heart J, 2006, 152(5): 8879-8914.
[15] Hang CL, Wang CP, Yip HK, et al. Early administration of intracoronary verapamil improves myocardial perfusion during percutaneous coronary interventions for acute myocardial infarction [J]. Chest, 2005, 128(4): 2593-2598.
[16] Beltrame JF, Turner SP, Leslie SL, et al. The angiographic and clinical benefits of mibefradil in the coronary slow flow phenomenon [J]. J Am Coll Cardiol, 2004, 44(1): 57-62.
[17] Huang RI, Patel P, Walinsky P, et al. Efficacy of intracoronary nicardipine in the treatment of no-reflow during percutaneous coronary intervention[J]. Catheter Cardiovasc Interv, 2006, 68(5): 671-676.
[18] Stone GW, Grines CL, Cox DA, et al. Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction[J]. N Engl J Med, 2002, 346 (13): 957-966.
[19] Petronio AS, De Carlo M, Ciabatti N, et al. Left ventricular remodeling after primary coronary angioplasty in patients treated with abciximab or intracoronary adenosine [J]. Am Heart J, 2005, 150(5): 1015.
[20] Montalescot G, Borentain M, Payot L, et al. Early vs late administration of glycoprotein IIb/IIIa inhibition in primary percutaneous coronary intervention of acute ST-segment elevation myocardial infarction: a meta-analysis[J]. JAMA, 2004, 292(3): 362-366.
[21] Zhao JL, Yang YJ, Zhang YH, et al. Chronic pretreatment of ACEI reduces no-reflow in patients with acute myocardial infarction treated with primary angioplasty[J]. Clin Cardiol, 2007, 30(3): 130-134.
[22] Burzotta F, Trani C, Romagnoli E, et al. Manual thrombus-aspiration improves myocardial reperfusion: the randomized evaluation of the effect of mechanical reduction of distal emboliza- tion by thrombus-aspiration in primary and rescue angioplasty (REMEDIA) trial [J]. JACC, 2005, 46(2): 371-376.
[23] Vlaar PJ, Svilaas T, van der Horst IC, et al. Cardiac death and reinfarction after 1 year in the Thrombus Aspiration during percutaneous coronary intervention in Acute myocardial infarction Study( TAPAS): a 1-year follow-up study[J]. Lancet, 2008, 371(9628): 1915-1920.
[24] Baim DS, Wahr D, George B, et al. Saphenous vein graft angioplasty free of emboli randomized (SAFER) trial investigators: randomized trial of a distal embolic protection device during percutaneous intervention of saphenous vein aorto-coronary bypass grafts[J]. Circulation, 2002, 105(11): 1285-1290.
[25] Stone GW, Webb J, Cox DA, et al. Myocardial efficacy and recovery by aspiration of liberated debris (EMERALD) investigators. distal microcirculatory protection during percutaneous coronary intervention in acute ST-segment elevation myocardial infarction : a randomized controlled trial[J]. JAMA, 2005, 293(9): 1063-1072.
[26] Antoniucci D, Valenti R, Migliorini A, et al. Direct infarct artery stenting without predilation and no-reflow in patients with acute my ocardial in farction[J]. Am heart J, 2001, 142(4): 684-690.
[27] Silva-Orrego P, Bigi R, Colombo P, et al. Direct stenting after thrombus removal before primary angioplasty in acute myocardial infarction[J]. J Interv Cardiol, 2008, 21(4): 300-306.